XTX Topco Ltd Acquires Shares of 13,851 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

XTX Topco Ltd acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 13,851 shares of the medical equipment provider's stock, valued at approximately $1,495,000.

Several other hedge funds also recently made changes to their positions in the company. CWM LLC boosted its stake in shares of Zimmer Biomet by 4.3% in the second quarter. CWM LLC now owns 6,485 shares of the medical equipment provider's stock valued at $704,000 after buying an additional 265 shares in the last quarter. Czech National Bank boosted its stake in shares of Zimmer Biomet by 6.6% during the 2nd quarter. Czech National Bank now owns 39,204 shares of the medical equipment provider's stock worth $4,255,000 after acquiring an additional 2,434 shares in the last quarter. M&G Plc boosted its stake in shares of Zimmer Biomet by 41.5% during the 2nd quarter. M&G Plc now owns 79,285 shares of the medical equipment provider's stock worth $8,642,000 after acquiring an additional 23,245 shares in the last quarter. NorthCrest Asset Manangement LLC grew its holdings in Zimmer Biomet by 1.1% in the second quarter. NorthCrest Asset Manangement LLC now owns 58,163 shares of the medical equipment provider's stock valued at $6,312,000 after purchasing an additional 629 shares during the last quarter. Finally, V Square Quantitative Management LLC increased its position in shares of Zimmer Biomet by 8.4% in the second quarter. V Square Quantitative Management LLC now owns 5,697 shares of the medical equipment provider's stock valued at $618,000 after buying an additional 441 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Trading Up 1.3 %

Shares of Zimmer Biomet stock traded up $1.44 during trading hours on Monday, hitting $109.47. The company's stock had a trading volume of 1,242,961 shares, compared to its average volume of 1,488,696. The business has a fifty day moving average of $107.55 and a 200 day moving average of $108.90. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $21.79 billion, a PE ratio of 20.81, a P/E/G ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same period last year, the company posted $1.65 earnings per share. The firm's revenue was up 4.1% compared to the same quarter last year. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of recent research reports. JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating on the stock in a research note on Monday, September 16th. Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. TD Cowen cut their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating for the company in a research report on Friday, September 6th. BTIG Research decreased their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a research report on Thursday, October 3rd. Finally, Wolfe Research started coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a "peer perform" rating for the company. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and an average price target of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.